Gynecologic Oncology Reports最新文献_第4页

Complete remission of small cell neuroendocrine carcinoma of the cervix treated with chemotherapy of paclitaxel, carboplatin, bevacizumab and pembrolizumab: A case report 紫杉醇、卡铂、贝伐单抗、派姆单抗联合化疗治疗宫颈小细胞神经内分泌癌完全缓解1例

IF 1.3

Gynecologic Oncology Reports Pub Date : 2026-06-01 Epub Date: 2026-05-25 DOI: 10.1016/j.gore.2026.102110

Reisa Kakubari, Yui Nonokawa, Yasuyuki Morita, Masayo Hosokawa, Keisuke Ogimoto, Eri Yamabe, Miho Kitai

{"title":"Complete remission of small cell neuroendocrine carcinoma of the cervix treated with chemotherapy of paclitaxel, carboplatin, bevacizumab and pembrolizumab: A case report","authors":"Reisa Kakubari, Yui Nonokawa, Yasuyuki Morita, Masayo Hosokawa, Keisuke Ogimoto, Eri Yamabe, Miho Kitai","doi":"10.1016/j.gore.2026.102110","DOIUrl":"10.1016/j.gore.2026.102110","url":null,"abstract":"<div><h3>Background</h3><div>Small cell neuroendocrine carcinoma (SCNEC) of the cervix is a rare and aggressive histological subtype associated with a poor prognosis. Here, we report a case of stage IVB cervical SCNEC that achieved a complete remission following first-line treatment with a combination of chemotherapy, anti-angiogenic therapy, and immune checkpoint inhibition.</div></div><div><h3>Case presentation</h3><div>A 42-year-old woman presented with genital bleeding and vaginal discharge. Computed tomography (CT) revealed a cervical lesion with peritoneal dissemination and multiple subcutaneous metastases. Positron emission tomography-computed tomography (PET-CT) confirmed <em>para</em>-aortic lymph node involvement and widespread metastatic disease. Cervical biopsy confirmed SCNEC, with positive immunohistochemical staining for synaptophysin and CD56.</div><div>The patient received first-line systemic therapy consisting of paclitaxel and carboplatin, in combination with bevacizumab and pembrolizumab. A total of seven cycles were administered, with no life-threatening adverse events. Follow-up PET-CT demonstrated resolution of previously identified lesions, consistent with a complete remission. At 15 months following initiation of therapy, the patient remains on maintenance treatment with bevacizumab and pembrolizumab, with no evidence of disease progression to date.</div></div><div><h3>Conclusion</h3><div>This case highlights the potential efficacy of immune checkpoint inhibitor-containing multimodality treatment regimens in the management of advanced cervical SCNEC.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"65 ","pages":"Article 102110"},"PeriodicalIF":1.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148184928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of preoperative frailty assessment on peri-operative complications and cancer related outcomes in advanced stage endometrial cancer 术前虚弱评估对晚期子宫内膜癌围手术期并发症及癌症相关结局的影响

IF 1.3

Gynecologic Oncology Reports Pub Date : 2026-06-01 Epub Date: 2026-05-29 DOI: 10.1016/j.gore.2026.102119

Christine I. Cho, Anne-Laure Strong, Brooke Arner, Christina Stetter, Edward Podczaski, Joel I. Sorosky, Mark S. Shahin, Shaina F. Bruce

{"title":"Impact of preoperative frailty assessment on peri-operative complications and cancer related outcomes in advanced stage endometrial cancer","authors":"Christine I. Cho, Anne-Laure Strong, Brooke Arner, Christina Stetter, Edward Podczaski, Joel I. Sorosky, Mark S. Shahin, Shaina F. Bruce","doi":"10.1016/j.gore.2026.102119","DOIUrl":"10.1016/j.gore.2026.102119","url":null,"abstract":"<div><h3>Objective</h3><div>The impact of pre-operative frailty on outcomes in patients with endometrial cancer is not well studied. The primary aim of this study was to assess the association between preoperative frailty scores and postoperative complications in patients with advanced-stage endometrial cancer.</div></div><div><h3>Methods</h3><div>This is a retrospective cohort study of patients who underwent hysterectomy for advanced-stage endometrial cancer at a single institution. Frailty was defined using the modified frailty index (mFI ≥ 2). Complications were measured with the Comprehensive Complication Index (CCI).</div></div><div><h3>Results</h3><div>A total of 62 were included; 17 met criteria for frail (F) based on mFI. In the non-frail (NF) cohort, 11 patients underwent open surgery vs. 4 in F. There were 34 NF patients in the MIS group, and 13 in F. Complications occurred in 29.4% F vs. 28.9% NF patients, p = 1.00), in the open surgery subgroup (50.0% F vs. 45.5% NF, p = 1.00) and in the minimally invasive surgery subgroup (23.1% F vs. 23.5% NF, p = 1.00). Those with complications had similar median CCI scores (22.6F vs. 24.2 NF, p = 0.84). Median days to adjuvant therapy were similar (39F vs. 43 NF, p = 0.32). Progression free survival (PFS) and overall survival (OS) was similar between groups.</div></div><div><h3>Conclusion</h3><div>Frailty was not associated with increased postoperative complication rate or worse survival in advanced endometrial cancer. Endometrial cancer surgery is largely performed minimally invasively which may be a factor that mitigates the adverse impact of frailty. Our small sample size limits interpretation: larger, multi-institutional studies are needed to determine whether surgical approach offsets the impact of frailty in this population.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"65 ","pages":"Article 102119"},"PeriodicalIF":1.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148185005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Improvement in chronic lymphedema in a gynecologic cancer survivor after starting GLP-1 receptor agonist therapy: A case report 开始GLP-1受体激动剂治疗后妇科癌症幸存者慢性淋巴水肿的改善：一个病例报告

IF 1.3

Gynecologic Oncology Reports Pub Date : 2026-06-01 Epub Date: 2026-06-05 DOI: 10.1016/j.gore.2026.102132

Andrea Fromson , Christelle David , Cody C. Andrews , Subha Hanif

{"title":"Improvement in chronic lymphedema in a gynecologic cancer survivor after starting GLP-1 receptor agonist therapy: A case report","authors":"Andrea Fromson , Christelle David , Cody C. Andrews , Subha Hanif","doi":"10.1016/j.gore.2026.102132","DOIUrl":"10.1016/j.gore.2026.102132","url":null,"abstract":"<div><div>BACKGROUND: Lower extremity and pelvic lymphedema is a difficult-to-treat and often debilitating sequela of gynecologic cancer treatment. Management has traditionally relied on lymphedema therapy, home manual massage drainage, compression garments, and pumps. These treatments can be time and labor intensive, and often fail to adequately manage symptoms. Patients with poorly controlled lymphedema are at increased risk of skin breakdown, infection, pain, and impaired mobility, all of which negatively impact quality of life. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are new medications being used for the treatment of type 2 diabetes and obesity, but there are reports of benefits for lymphedema as well. Thus far, most case reports have focused on patients with upper extremity lymphedema.</div><div>CASE PRESENTATION: Here, we present a case of chronic severe lower extremity and pelvic lymphedema which was reversed with use of a GLP-1 RA. Previously our patient had severe, debilitating lymphedema for almost two decades. On starting a GLP-1 RA, she had marked improvement in her lymphedema symptoms, function, and quality of life.</div><div>CONCLUSIONS: GLP-1 RAs show promising benefit as a new treatment for chronic, uncontrolled lymphedema; however, there are currently no reported uses in lower extremity edema. This case report provides one example of GLP-1 RA effectiveness for lower extremity and pelvic edema and supports the case for further dedicated research.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"65 ","pages":"Article 102132"},"PeriodicalIF":1.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148241269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hypercalcemia in poorly differentiated endometrial cancer: a report of two cases 低分化子宫内膜癌伴高钙血症：附2例报告

IF 1.3

Gynecologic Oncology Reports Pub Date : 2026-06-01 Epub Date: 2026-06-06 DOI: 10.1016/j.gore.2026.102131

Alina Zatsepina , Uliana Cheliadinova , Kripa Tiwari , Hao Li , Vipluv Singh , Rafi Mohamed Shaji , Christine Resta , Yiqing Xu

{"title":"Hypercalcemia in poorly differentiated endometrial cancer: a report of two cases","authors":"Alina Zatsepina , Uliana Cheliadinova , Kripa Tiwari , Hao Li , Vipluv Singh , Rafi Mohamed Shaji , Christine Resta , Yiqing Xu","doi":"10.1016/j.gore.2026.102131","DOIUrl":"10.1016/j.gore.2026.102131","url":null,"abstract":"<div><h3>Background</h3><div>Hypercalcemia as a paraneoplastic syndrome is associated with poor prognosis. It is most commonly caused by parathyroid hormone-related protein (PTHrP) production, less commonly by bony metastases, and very rarely by ectopic parathyroid hormone (PTH) secretion. Hypercalcemia in endometrial cancer is relatively rare.</div></div><div><h3>Case presentation</h3><div>We present two cases of hypercalcemia in patients with poorly differentiated endometrial cancer, both of whom had elevated PTH levels and no evidence of parathyroid disease or bone metastases at baseline. In the first case, hypercalcemia rapidly progressed in parallel with metastatic disease, leading to clinical deterioration and death within one month. In the second case, calcium and PTH levels improved with systemic chemotherapy and cinacalcet but recurred with disease progression, supporting a tumor-driven mechanism. Both cases demonstrated aggressive histology and mismatch repair deficiency. Notably, hypercalcemia and PTH levels closely tracked tumor burden and clinical course.</div></div><div><h3>Conclusion</h3><div>Ectopic PTH secretion should be considered in patients with endometrial cancer presenting with hypercalcemia and elevated PTH in the absence of parathyroid pathology. Recognition of this rare entity is important to avoid misdiagnosis and to guide appropriate oncologic management.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"65 ","pages":"Article 102131"},"PeriodicalIF":1.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148241270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Master Class: Writing a Case Report – Reflections on a Recently Published Case Report 大师班：撰写个案报告-对最近发表的个案报告的思考。

IF 1.5

Gynecologic Oncology Reports Pub Date : 2026-06-01 Epub Date: 2026-06-08 DOI: 10.1016/j.gore.2026.102133

Jennifer McEachron, Susan C. Modesitt, Jamie N. Bakkum-Gamez

引用次数: 0

Ecthyma gangrenosum in a patient with metastatic leiomyosarcoma undergoing chemotherapy: a case report 转移性平滑肌肉瘤接受化疗时的坏疽性湿疹1例报告

IF 1.3

Gynecologic Oncology Reports Pub Date : 2026-06-01 Epub Date: 2026-06-03 DOI: 10.1016/j.gore.2026.102129

Grace Getman , Taryn Boucher , Vicki Keedy , Melinda New , Alison Barlow , Lauren Prescott

{"title":"Ecthyma gangrenosum in a patient with metastatic leiomyosarcoma undergoing chemotherapy: a case report","authors":"Grace Getman , Taryn Boucher , Vicki Keedy , Melinda New , Alison Barlow , Lauren Prescott","doi":"10.1016/j.gore.2026.102129","DOIUrl":"10.1016/j.gore.2026.102129","url":null,"abstract":"<div><h3>Background</h3><div>Ecthyma gangrenosum (EG) is a rare necrotizing skin infection most commonly associated with <em>Pseudomonas</em> in immunocompromised patients. Increasingly, EG has been identified in nonbacteremic or immunocompetent patients with various microbial etiologies, expanding its range of clinical presentations.</div></div><div><h3>Case presentation</h3><div>A 40 year-old patient with metastatic leiomyosarcoma presented two-weeks after initiating chemotherapy with multiple necrotic vulvar lesions with an erythematous rim, characteristic of EG. She had no systemic symptoms. She was treated empirically with ciprofloxacin and wound cultures confirmed <em>Pseudomonas</em> infection. The lesions resolved with antibiotic treatment alone, not requiring surgical intervention.</div></div><div><h3>Conclusion</h3><div>This represents the second reported case of EG in a patient with gynecologic malignancy. It highlights that EG may present without systemic symptoms, even in high-risk neutropenic patients, and underscores the importance of early detection and antipseudomonal antibiotic initiation to prevent adverse outcomes associated with EG in vulnerable oncologic populations.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"65 ","pages":"Article 102129"},"PeriodicalIF":1.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148241272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Trastuzumab deruxtecan (T-DXd) in HER2-expressing gynecological malignancies: Clinical evidence, safety profile, and future directions 曲妥珠单抗deruxtecan （T-DXd）治疗表达her2的妇科恶性肿瘤：临床证据、安全性和未来方向

IF 1.3

Gynecologic Oncology Reports Pub Date : 2026-06-01 Epub Date: 2026-05-24 DOI: 10.1016/j.gore.2026.102116

Heena Arshad , Inamullah Arshad , Hamza Massab Rehman , Safia Bibi , Muhammad Hassaan Javaid , Ruben Simon Roy

{"title":"Trastuzumab deruxtecan (T-DXd) in HER2-expressing gynecological malignancies: Clinical evidence, safety profile, and future directions","authors":"Heena Arshad , Inamullah Arshad , Hamza Massab Rehman , Safia Bibi , Muhammad Hassaan Javaid , Ruben Simon Roy","doi":"10.1016/j.gore.2026.102116","DOIUrl":"10.1016/j.gore.2026.102116","url":null,"abstract":"<div><div>Endometrial, ovarian, and cervical cancers in advanced or recurrent stages are associated with unfavorable outcomes, emphasizing the need for effective targeted approaches. While HER2 has been identified as a key biomarker in selected high-grade tumors, prior HER2-targeted therapies have yielded inconsistent results. This review discusses the underlying biology, clinical outcomes, safety considerations, and evolving application of trastuzumab deruxtecan (T-DXd) in HER2-positive gynecological cancers. T-DXd is a HER2-directed antibody-drug conjugate of a monoclonal antibody linked to a potent topoisomerase I inhibitor, allowing targeted delivery and a bystander killing effect. Evidence from trials such as DESTINY-PanTumor02 and STATICE demonstrates meaningful and sustained responses across HER2-positive gynecological malignancies, with the greatest benefit observed in IHC 3 + tumors. While the overall safety profile of T-DXd is manageable, interstitial lung disease or pneumonitis represents a key adverse event and requires timely recognition and intervention. T-DXd represents an emerging therapeutic option for HER2-positive gynecological malignancies after prior treatment, especially in advanced lines of therapy. Further studies focusing on biomarker refinement, sequencing approaches, and toxicity mitigation will be key to establishing its place in clinical practice.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"65 ","pages":"Article 102116"},"PeriodicalIF":1.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148184931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Three-dimensional reconstruction technology facilitates surgical planning for endometrial cancer with pelvic ectopic kidney: a case report 三维重建技术有助于子宫内膜癌伴盆腔异位肾的手术计划：1例报告

IF 1.3

Gynecologic Oncology Reports Pub Date : 2026-06-01 DOI: 10.1016/j.gore.2026.102128

Yachai Li , Jiarui Mi , Peixuan Wang , Ke Zhang , Liwei Yan , Yuanmei Deng , Meng Li

{"title":"Three-dimensional reconstruction technology facilitates surgical planning for endometrial cancer with pelvic ectopic kidney: a case report","authors":"Yachai Li , Jiarui Mi , Peixuan Wang , Ke Zhang , Liwei Yan , Yuanmei Deng , Meng Li","doi":"10.1016/j.gore.2026.102128","DOIUrl":"10.1016/j.gore.2026.102128","url":null,"abstract":"<div><h3>Background</h3><div>Endometrial cancer co-occurring with a pelvic ectopic kidney is an extremely rare condition. To prevent accidental intraoperative injury to the ectopic kidney and its aberrant vasculature, digital model obtained through three-dimensional (3D)reconstruction was used to clearly delineate the complex spatial relationship between the tumor and the ectopic renal anatomy, offering a novel strategy for managing this type of complex cases.</div></div><div><h3>Case presentation</h3><div>A 45-year-old woman of Chinese ethnicity was diagnosed with endometrial cancer. Preoperative imaging revealed an ectopic kidney in the right pelvis. Based on CT data, we reconstructed the digital 3D models of the urinary system and the tumor using Mimics medical 23.0 (Materialise NV, Belgium)to evaluate anatomical variations and assess surgical risks. The 3D model clearly illustrated the spatial relationships among the ectopic kidney, the tumor, adjacent vessels, and surrounding organs, facilitating optimized surgical planning. During the operation, the model demonstrated high concordance with the actual anatomy, and no unexpected injuries occurred.</div></div><div><h3>Conclusion</h3><div>The use of 3D-reconstructed model facilitates an intuitive visualization of intricate anatomical variations, which may contribute to enhanced surgical safety for patients presenting with gynecological tumors and concurrent rare congenital abnormalities, suggesting that this approach holds promise for future clinical integration.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"65 ","pages":"Article 102128"},"PeriodicalIF":1.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148184934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Multimodal therapy for ovarian cancer with brain metastases diagnosed synchronously at the initial phase: case report of a long-term survivor with comprehensive literature review 多模式治疗在初始阶段同步诊断为脑转移的卵巢癌：一名长期幸存者的病例报告，并进行全面的文献复习

IF 1.3

Gynecologic Oncology Reports Pub Date : 2026-06-01 Epub Date: 2026-05-25 DOI: 10.1016/j.gore.2026.102124

Wissam Arab , Nadine El Kassis , Clement Khoury , Hussein Mansour , Georges Chahine , David Atallah

{"title":"Multimodal therapy for ovarian cancer with brain metastases diagnosed synchronously at the initial phase: case report of a long-term survivor with comprehensive literature review","authors":"Wissam Arab , Nadine El Kassis , Clement Khoury , Hussein Mansour , Georges Chahine , David Atallah","doi":"10.1016/j.gore.2026.102124","DOIUrl":"10.1016/j.gore.2026.102124","url":null,"abstract":"<div><div>Brain metastases from epithelial ovarian cancer (EOC) are uncommon and usually occur during disease recurrence. Their occurrence at the initial phase of the disease is particularly rare. Overall prognosis remains poor despite the employment of a multimodal therapy including surgery, radiotherapy and chemotherapy, with reported progression-free survivals of approximately 12 months. The role of targeted therapies in this setting, particularly poly ADP-ribose polymerase inhibitors (PARPi), remains incompletely defined.</div><div>We report the case of a 45-year-old woman with high-grade serous ovarian carcinoma who developed symptomatic brain metastases 6 days following primary debulking surgery (PDS). A BRCA1 mutation was identified on tumor sequencing and was subsequently confirmed as a germline pathogenic variant. Complete remission was obtained using stereotactic radiotherapy to the brain lesions, followed by platinum-based chemotherapy and maintenance therapy with bevacizumab and olaparib. 45 months since the initiation of olaparib, the patient still has no evidence of disease.</div><div>PARPi are a promising maintenance therapy to control EOC with secondary brain metastases, particularly in PARPi-naïve disease. Their role in this setting remains emerging and primarily supported by limited case reports and small series. Further studies are required to better define their role.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"65 ","pages":"Article 102124"},"PeriodicalIF":1.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148184927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Granulosa cell tumors and menopausal hormone therapy: A narrative review 颗粒细胞瘤和绝经期激素治疗：一个叙述性的回顾

IF 1.3

Gynecologic Oncology Reports Pub Date : 2026-06-01 DOI: 10.1016/j.gore.2026.102123

Abigail Shore , Lanlan Fang , Shelley Hewins , David G. Huntsman , Lesa M. Dawson

{"title":"Granulosa cell tumors and menopausal hormone therapy: A narrative review","authors":"Abigail Shore , Lanlan Fang , Shelley Hewins , David G. Huntsman , Lesa M. Dawson","doi":"10.1016/j.gore.2026.102123","DOIUrl":"10.1016/j.gore.2026.102123","url":null,"abstract":"<div><div>Adult granulosa cell tumors (GCT) are rare sex cord stromal tumors of the ovary, characterized by distinct histologic features and the near ubiquitous presence of a recurrent somatic mutation in the FOXL2 gene. Although GCT have a favorable prognosis compared to other ovarian cancer subtypes, recurrences typically occur later than other ovarian cancers; usually between 4–8 years after initial diagnosis. Once recurrence is diagnosed, cure through surgery is rare and few effective systemic therapies exist. The median age at GCT presentation is between 46–50 years old, and many cases occur in premenopausal women. GCT are hormonally active tumors, with many of the tumors secreting estrogen. Hormone receptors, including progesterone and estrogen receptors are often expressed in these tumors.</div><div>Younger GCT patients who undergo the recommended surgical staging procedure, experience premature surgical menopause, which is associated with vasomotor symptoms, increased risk of osteoporosis and cardiovascular events as well as reduced cognitive and sexual functioning. Menopausal hormone therapy (MHT) mitigates these risks and is recommended for individuals with premature menopause. In GCT patients, most guidelines caution against MHT use, due to perceived risk associated with the hormonally and endocrinologically active nature of these tumors. This narrative review outlines the hormonal nature of GCT and summarizes and synthesizes the evidence relating to possible safety and risk of MHT use in GCT patients.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"65 ","pages":"Article 102123"},"PeriodicalIF":1.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148184932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0